Consulting company currently analyzing the biosimilars industry in cee.
We’re recruiting biosimilar industry experts for interviews related to biosimilars market access (we’re looking to conduct 90-minute interviews for which we’re willing to compensate the interviewees).
Please, see below the list of our key areas of interest. If you feel comfortable with discussing these, please provide the cee countries and respective information areas you are knowledgeable on. Additionally, please provide your requested compensation/rate. Ideally we would like to interview the experts as soon as possible/ this week. We are flexible with time, so it can be early mornings or evening / nights or throughout the day.
Prior to the call we will provide you with a more detailed list of the questions so that you are sure you can discuss these
the interview will focus on 3 areas related to biosimilar market access:
1. Market size – historical and expected biosimilar growth in particular cee countries (overall, relative to originals, by channel, and by biological class)
2. Regulation – market access processes and requirements specific to entering the particular cee country markets (pharmaceutical market authorization, national labelling approval, pricing and reimbursement, substitution and interchangeability)
3. Go to market – sales, logistics and supply chain (key stakeholders and decision makers regarding biosimilar uptake for hospitals and pharmacies, sales/ tender processes in retail and hospital channels, legal requirements, demand creation, wholesaler and distribution economics, etc.)+4 Other Responses
Need an industry expert on immunology market. He/she should have extensive knowledge on one of these market segments such as:
glucocorticoids, non-biologic disease modifying drugs and biologics;
ankylosing spondylitis, crohn’s disease, multiple sclerosis, psoriasis, rheumatoid arthritis, systemic lupus erythematosus, ulcerative colitis;
tumor necrosis factor- alpha, interleukin-6 and receptor, interleukin – 1,2,5,12,17 & 23 and receptors)
(humira (adalimumab), remicade (infliximab), enbrel (etanercept), rituxan (rituximab), stelara (ustekinumab), progra (tacrolimus), cimzia (certolizumab pegol), simponi (golimumab), entyvio (vedolizumab).
The expert should be able to provide insights on the following for the above: market size, company shares, market trends, and price trends. As well as knowledge regarding country-wide usage for us and europe regarding the price trends and market shares will be helpful.
+12 Other Responses